Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 25, Issue 28, 2007, Pages 4466-4471

  Spriggs, David R ^a   Brady, Mark F ^b   Vaccarello, Luis ^b   Clarke Pearson, Daniel L ^b   Burger, Robert A ^b   Mannel, Robert ^b   Boggess, John F ^b   Lee, Roger B ^b   Hanly, Mark ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAZARD RATIO; HEARING DISORDER; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MORTALITY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE TUBE TUMOR; WEIGHT REDUCTION; ZYGOTE; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 35348827299     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3846     Document Type: Article

References (24)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
3. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23, 1995 (3 suppl 6)
4. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
5. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
6. Omura GA, Brady MF, Look KY, et al: Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study. J Clin Oncol 21:2843-2848, 2003
7. Donehower RC, Rowinsky EK, Grochow LB, et al: Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 71:1171-1177, 1987
8. Schiller JH, Storer B, Tutsch K, et al: A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 21:9-14, 1994 (5 suppl 8)
9. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
10. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 10:275-278, 1992
11. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997
12. Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
13. Abu-Rustum NR, Aghajanian C, Barakat RR, et al: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:S15-62-S15-67, 1997 (5 suppl 15)
14. Georgiadis MS, Schuler BS, Brown JE, et al: Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer. J Clin Oncol 15:735-743, 1997
15. Rose P, Nerenstone S, Brady M, et al: Secondary surgical cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. N Engl J Med 351:2489-2497, 2004
16. Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecology cancer, in Deppe G (ed): Chemotherapy of Gynecology Cancer (ed 2). New York, NY, Alan R Liss, 1990, pp 63-97
17. Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 39:499-503, 1983
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 35:185-206, 1972
19. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin refractory or mitoxantrone refractory breast cancer: A phase I/II trial of 96 h infusion. J Clin Oncol 12:1621-1629, 1994
22. Breathnach OS, Georgiadis MS, Schuler BS, et al: Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin Cancer Res 6:2670-2676, 2000
23. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000
24. ICON3 Investigators: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360:505-515, 2002